Dana-farber Cancer Institute

This study tested two immunotherapy drugs, durvalumab and tremelimumab, in people with malignant pleural mesothelioma, a rare cancer of the lung lining. The trial enrolled 19 participants whose cancer had worsened after standard chemotherapy. The goal was to see if the drug combi…

This study tested a drug called abemaciclib in 27 people with a hard-to-treat, advanced breast cancer (triple-negative, retinoblastoma-positive). The goal was to see if the drug could shrink tumors or slow the disease. The trial was stopped early, so results are limited.

This study tested a new drug, GDC-0084, combined with the standard drug trastuzumab (Herceptin) in 17 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the combination could shrink or control brain tumors. The trial was terminated early,…

This study looked at whether two immunotherapy drugs, ipilimumab and nivolumab, could help people with advanced non-small cell lung cancer who had not received prior treatment. Only 5 participants were enrolled before the study was stopped early. The goal was to see how well the …

This study tested a drug called neratinib, alone or with another drug (fulvestrant), in 21 people with a specific type of advanced breast cancer (HER2-positive and ER-positive). The goal was to see if the combination could slow cancer growth better than neratinib alone. The trial…

This study tested whether adding the immunotherapy drug avelumab to standard radiation could help treat muscle-invasive bladder cancer in patients who cannot receive the usual chemotherapy. Fourteen participants received the combination therapy. The goal was to see if the cancer …